Rationale and Design of the German-speaking Myeloma Multicenter Group (GMMG) Trial HD6

A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction/consolidation and Lenalidomide Maintenance in Patients with Newly Diagnosed Myeloma

by Hans Salwender, Uta Bertsch, Axel Benner, Marc-Steffen Raab, Jens Hillengaß, Dirk Hose, Stefanie Huhn, Michael Hundemer, Anna Jauch, Andrea Seidel-Glätzer, Hartmut Goldschmidt · 2019